Cost-Effective Biomarkers Ready at our fingertips
Category Archives: 2018 17th International Kidney Cancer Symposium
Trump National Doral Miami Hotel, Miami, FL November 2-3, 2018
Cell-free DNA (cfDNA)
RCC Profiling
An Empirical Approach to Dissect the TME in RCC
The impact of the stool microbiome in RCC
Single Cell RNA-Sequencing in RCC
Renal mass biopsy in 2018: When, where and how?
Emerging Ablative Technologies – Whats New And Is It Better?
Overdiagnosis and the Harms of Overtreatment of Renal Cell Carcinoma
The Radiological Biopsy: Are we there yet? Imaging based renal mass diagnosis
Pro vs Con for Enucleation
Enucleation of Renal Mass: Why Would You Not Keep Your Distance?
Laparoscopic Vs Robotic Radical Nephrectomy: What are the Costs and Benefits?
RCC: Putting Frontline Combination Data into Perspective
Metastatic Renal Cell Cancer: Who Deserves Monotherapy?
Beyond Checkpoint Blockade
Tayloring Therapy: Therapy Intensification and Discontinuation
Phase II trial of intermittent nivolumab
Ongoing Clinical Trial Update: A Pilot Study of Pre-surgical Tremelimumab with or without Tissue Cryoablation
Rationally Targeting the Bone with Radium Plus Cabozantinib
Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib
PDIGREE
Safety and efficacy of checkpoint inhibitors
CheckMate 214 Retrospective Analyses
An Evaluation of the Role of Cytoreductive Nephrectomy in Patients with Sarcomatoid RCC
Neoadjuvant PD1 Blockade to Prime the Immune System
Combination Checkpoint Blockade with Surgery
What is the Next Cytoreductive Surgical Trial?
Creating Synergy in RCC: Collaborative Approaches to Value
Engaging Clinical Trialists in the Community Setting
Exploiting oncometabolite-induced DNA repair defects
Adenosine Pathway Inhibitors
Neovax: From Translation to Bedside
Targeting Epigenetics and Chromatin Remodeling Genes
Neovax: From Translation to Bedside
Novel metabolic insights into RCC biology and immune response
Secreted PD-L1 Splice Variant that Covalently Dimerizes and Mediates Immunosuppression
Targeting Vulnerabilities Arising from Dysregulated Histone Demethylase Function in Kidney Cancer
Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases
LARCG Latin American Renal Cancer Group
UPDATES LATIN AMERICAN COOPERATIVE ONCOLOGY GROUP (LACOG)
Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose-escalation stage in patients with treatment-naïve advanced renal cell carcinoma
Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma
Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma